|
|||||
|
|
[I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors |
|
| Authors: | Jean-Louis Baulieu, Isabelle Resche, Manuel Bardies, Alain Faivre Chauvet, Joseph Lecloirec, Jean-Pierre Malhaire, Eric Thomas, Patrick Faurous, Genevi ve Sassolas, L andre Pourcelot, Jean-Fran ois Chatal, Denis Guilloteau,Jean-Claude Besnard |
| Affiliation: | 1 Department of Nuclear Medicine, Hôpital Bretonneau, Tours, France 2 Department of Nuclear Medicine, Centre René Gauducheau, Nantes, France 3 Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France 4 Department of Radiotherapy, Hôpital Augustin Morvan, Brest, France 5 Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France 6 Department of Nuclear Medicine, Centre Val d’Aurelle, Montpellier, France 7 Department of Nuclear Medicine, Hôpital Neuro-cardiologique, Lyon, France |
| Abstract: | Dosimetry and therapeutic application of [131I]-Tyr3-octreotide were evaluated in three patients with metastatic paraganglioma and carcinoid tumor. The in vitro stability of [131I]-Tyr3-octreotide was verified. Tumor uptake and residence time were between 0.02 and 0.1% and 0.5 to 9.8 h, respectively. The calculated tumor radiation doses were between 0.105 and 0.696 mGy·MBq−1. No intolerance or adverse effects were observed after the therapeutic doses (3.3–6.6 GBq). A partial tumor response was obtained in one patient and no response occurred in two patients. |
| Keywords: | Internal radiotherapy Somatostatin receptors Somatostatin analogs [131I]-Tyr3-octreotide Malignant paraganglioma Carcinoid tumor |
| 本文献已被 ScienceDirect 等数据库收录！ | |